ReviewCritical reviews in oncology/hematology2017
Advances in the management of HER2-positive early breast cancer.
Review in Critical reviews in oncology/hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.Breast cancer research : BCR · 2018Trial
- Enhanced Payload Release Enables Disitamab Vedotin to Surpass Trastuzumab Emtansine and Retain Efficacy in Acquired Resistance to Clinical Anti-HER2 Therapies.Pharmaceutics · 2026Article
- Computational Characterization of Nabilone-Induced Disruption of the CB2-HER2 Receptor Complex in HER2+ Breast Cancer.Bioinformatics and biology insights · 2026Article
- Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model.Biomolecules & biomedicine · 2024Article
- Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.Journal of hematology & oncology · 2023Review
- Neratinib for HER2-positive breast cancer with an overlooked option.Molecular medicine (Cambridge, Mass.) · 2023Review
- Structure-activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR.Archives of pharmacal research · 2022Article
- Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world.Frontiers in molecular biosciences · 2022Article
- Probing GPCR Dimerization Using Peptides.Frontiers in endocrinology · 2022Review
- How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer.Oncology and therapy · 2021Review
- FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036.NPJ breast cancer · 2021Article
- PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.Journal of clinical laboratory analysis · 2021Article
- Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.International journal of molecular sciences · 2021Review
- Applying the New Guidelines of HER2 Testing in Breast Cancer.Current oncology reports · 2020Review
- Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.JCI insight · 2020Article
- Somatic Mutations inJournal of oncology · 2020Review
- GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.Molecular carcinogenesis · 2019Article
- Therapeutic targeting of HER2-CBProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer.Cancers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
Abstract
While trastuzumab is firmly established as the cornerstone of therapy for both early and advanced breast cancer expressing human epidermal growth factor receptor 2 (HER2), many patients either do not respond to trastuzumab treatment or progress following therapy. Improved understanding of breast cancer biology, particularly the complex signaling interactions managed by the HER family of receptors, have resulted in development of several novel HER2-directed therapies and combinations. This article will review the novel approaches to HER2 targeting that have been developed in recent years, with particular focus on results from these approaches in early breast cancer, and will discuss strategies to improve the tolerability of HER2-directed therapies, including prevention of cardiac toxicity and diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.